Publication type: Conference poster
Type of review: No review
Title: The burden of cystic fibrosis beyond medical costs in Switzerland
Authors: Tzogiou, Christina
Pöhlmann, Johannes
Mattli, Renato
Jung, Andreas
et. al: No
Conference details: 44th European Cystic Fibrosis Conference, digital, 9-12 June 2021
Issue Date: 2021
Language: English
Subject (DDC): 362.1041: Health economics
616: Internal medicine and diseases
Abstract: Objectives: In Switzerland, about 1,000 people live with cystic fibrosis (CF). Despite advances in treatment and care, CF continues to burden affected individuals and healthcare systems in several ways. Patients and their caregivers incur costs beyond medical expenses that are not covered by the health or disability insurance. The aim of this study is to assess these costs in terms of non-medical expenses, quality of life and subjective burden associated with CF as well as production losses, that are affecting the entire society. Methods: We conducted a prevalence-based, cost-of-illness study. Electronic questionnaires were sent to adult CF patients, their caregivers, and parents of children with CF. Parents completed the questionnaire for their child, and the questions related to the production losses and burden assessment for themselves. Results: The survey covered 267 out of 973 (27.4%) patients in Switzerland. Extrapolated to all CF patients in Switzerland, direct non-medical costs of CF amount to CHF 2.7 million and total production losses to CHF 15.7 million annually. Production losses due to premature death account for the largest share of these costs, followed by production losses due to presenteeism. For adult CF patients the mean EQ-5D index score was 0.84 and the Visual Analogue Scale (VAS) score 68.93. Among children with CF the VAS score was 83.99. The subjective burden of CF measured by the BSFC-s (0: lowest; 30: highest) averaged at 11.1 for caregivers and at 11.9 for parents. Conclusions: CF imposes substantial costs on patients, their caregivers and the society in Switzerland, while the average quality of life of individuals with CF can be considered as good. The level and composition of these costs should raise awareness among policymakers.
Fulltext version: Published version
License (according to publishing contract): Licence according to publishing contract
Departement: School of Management and Law
Organisational Unit: Winterthur Institute of Health Economics (WIG)
Appears in collections:Publikationen School of Management and Law

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.